Quantum Blue® fCAL Citation Lobatón T, Rodríguez-Moranta F, Lopez A, Sánchez E, Rodríguez-Alonso L, Guardiola J. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis. 2013 Apr;19(5):1034-42. doi: 10.1097/MIB.0b013e3182802b6e. PMID: 23470502 “FC determined by QPOCT was an accurate surrogate marker of “endoscopic remission” in UC presented a
Continue Reading →
- info@buhlmannlabs.ch
- +41 61 487 12 12
Blog Archives
Wright, E.K. et al., Cost-effectiveness of Crohn’s disease post-operative care, World J Gastroenterol. 2016 Apr 14;22(14):3860-8. doi: 10.3748/wjg.v22.i14.3860. Shentova, R. et al., 2016, Diagnostic Value of Fecal Calprotectin Point of Care Testing in the Pediatric Practice, Merit Res. J. Med. Med. Sci. Available online http://www.meritresearchjournals.org/mms/index.htm Gauss, A. et al., Quality of Life Is Related to
The BÜHLMANN GanglioCombi™ MAG ELISA was recently utilized in a case-control study in French Polynesia focusing on individuals diagnosed with Guillain-Barré Syndrome (GBS). See publication below: Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study Learn More
Continue Reading →
At the ECCO IBD meeting 2016 in Amsterdam the first poster on the performance of the BÜHLMANN Quantum Blue® Infliximab rapid test was presented, including data on high correlations to the Sanquin and Leuven infliximab ELISA tests. The reaction from attendees was enthusiastic, and the application for a high quality quantitative rapid tool to measure
Social Links